
Teva Pharmaceuticals and Viatris have won an appeal to revive their challenges against Johnson & Johnson's patent for the schizophrenia drug Invega Sustenna. The U.S. Court of Appeals for the Federal Circuit ruled that the patent may be invalid, directing a New Jersey federal court to reconsider. J&J intends to continue defending its intellectual property, while Teva looks forward to offering low-cost medication. Viatris, now part of the lawsuit, has yet to respond. Invega Sustenna generated over $4.1 billion in global sales last year, with a significant portion in the U.S., prompting lawsuits against Teva and Mylan (now Viatris) for patent infringement.
Like
Save
Share